More data does not automatically create better evidence. Pharmaceutical manufacturers have access to more healthcare data than ever, yet fragmented evidence generation can still leave critical questions unanswered.
When Real-World Evidence (RWE), Health Economics and Outcomes Research (HEOR), regulatory, and market access activities operate as separate workstreams, evidence may satisfy individual requirements without creating a cohesive value story across the product lifecycle.
In this POV, Dr. Ramaa Nathan explores how connected RWE and HEOR strategies can transform individual studies into continuous evidence assets that support decisions from early development through post-launch.
Read to learn how:
- RWE should complement randomized controlled trials by addressing evidence gaps they were not designed to resolve.
- Integrated RWE and HEOR planning can support clinical development, regulatory approval, health technology assessment, payer negotiations, provider adoption, and lifecycle management.
- To meet U.S. and European decision-makers’ expectations for fit-for-purpose, relevant, reliable, and transparent evidence.
- Lifecycle evidence strategies can help manufacturers generate value across multiple stakeholder decisions instead of reacting to isolated requirements.
- EVERSANA applies integrated evidence generation in practice with real-world case studies.
Discover the true strategic advance of RWE: a connected evidence ecosystem where every insight builds on the last and informs the decisions ahead.
Author
Ramaa Nathan serves as the VP, Data Science and Real World Evidence at EVERSANA with several years of experience in the financial and healthcare industries. Ramaa is a data scientist and statistician with extensive…
After leaving the Mayo Clinic, from 1988 to 2007, he held academic, clinical and administrative leadership positions as Chief of Cardiac Surgery, Pediatric Cardiac Surgery and Heart Transplantation at several Academic Hospitals in the…